Home > Boards > US Listed > Medical - Drugs > AVEO Pharmaceuticals, Inc. (AVEO)

This TiVo drug actually has less side effects

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Gungadin1 Member Profile
 
Followed By 1
Posts 538
Boards Moderated 0
Alias Born 07/17/19
160x600 placeholder
AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer Business Wire - 1/6/2020 7:00:00 AM
AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Business Wire - 12/4/2019 7:00:00 AM
AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference Business Wire - 11/26/2019 7:00:00 AM
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors Business Wire - 11/19/2019 7:00:00 AM
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Business Wire - 11/18/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:16:33 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 7:15:55 AM
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire - 11/12/2019 7:00:00 AM
AVEO Oncology & Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination w... Business Wire - 11/7/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:02:44 AM
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma Business Wire - 11/4/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 9:12:29 AM
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (... Business Wire - 9/30/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2019 7:24:47 AM
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire - 9/26/2019 7:00:00 AM
AVEO Oncology & EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell... Business Wire - 9/23/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 5:23:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 4:11:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 9:44:00 AM
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carc... Business Wire - 9/10/2019 6:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 5:26:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 7:06:22 AM
AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire - 8/8/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 6:16:14 AM
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology Business Wire - 8/1/2019 6:00:00 AM
Gungadin1   Sunday, 10/06/19 09:48:05 PM
Re: Biotech Pharmer post# 4932
Post # of 5243 
This TiVo drug actually has less side effects than sorenfinab.combined with immunotherapy drugs more than likely will be more effective.I hate hand foot syndrome. A second and thirs line will be easier to get approved. And who knows perhaps 1st line with combos of immunotherapy drugs like optivo and keytruda.I hoping for good news on this . I'm on pkeytruda and am waiting for inlyta. To be aroves and sent to be although I'm experiancing headaches and joint pain im hoping it will subside .it be caused by something else.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist